Skip to content

King Pharmaceuticals KG Commercial Auto Liability — Year 2

Other product segments

All other lines
32.4%
General Liability
10.4%
European Hospital Liability
7.1%
International
6.9%

Similar metrics at other companies

Kemper logo
KMPRCommercial Automobile Insurance—Liability — Year 2
46.6%-5.5pp
CNA Financial logo
CNACommercial Auto — Year 2
22.5%+0.2pp
United Fire Group logo
UFCSCommercial automobile — Year 2
21.3%+0.3pp
United Fire Group logo
UFCSCommercial other liability — Year 2
14.1%-0.6pp
Kemper logo
KMPRCommercial Automobile Insurance—Physical Damage — Year 2
100%0.0pp
Kemper logo
KMPRCommercial Automobile Insurance—Liability — Year 1
19.1%-2.4pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearTwo.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's commercial auto liability — year 2.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's commercial auto liability — year 2?
King Pharmaceuticals (KG) reported commercial auto liability — year 2 of 17.6% in Q4 2025.
What does commercial auto liability — year 2 mean?
This metric tracks the loss development or financial performance data for the commercial auto liability segment during the second year of the policy cycle. It provides insight into the maturation of claims and the accuracy of initial reserve estimates. It is a key component of the loss development triangle analysis.